Unknown

Dataset Information

0

Epigenetic silencing of MEIS2 in prostate cancer recurrence.


ABSTRACT: BACKGROUND:Current diagnostic and prognostic tools for prostate cancer (PC) are suboptimal, resulting in overdiagnosis and overtreatment of clinically insignificant tumors. Thus, to improve the management of PC, novel biomarkers are urgently needed. RESULTS:In this study, we integrated genome-wide methylome (Illumina 450K DNA methylation array (450K)) and RNA sequencing (RNAseq) data performed in a discovery set of 27 PC and 15 adjacent normal (AN) prostate tissue samples to identify candidate driver genes involved in PC development and/or progression. We found significant enrichment for homeobox genes among the most aberrantly methylated and transcriptionally dysregulated genes in PC. Specifically, homeobox gene MEIS2 (Myeloid Ecotropic viral Insertion Site 2) was significantly hypermethylated (p??500 PC and AN tissue samples in total (TCGA cohort analyzed by 450K and RNAseq). Furthermore, in three independent radical prostatectomy (RP) cohorts (n?>?700 patients in total), low MEIS2 transcriptional expression was significantly associated with poor biochemical recurrence (BCR) free survival (p?=?0.0084, 0.0001, and 0.0191, respectively; log-rank test). Next, we analyzed another RP cohort consisting of >?200 PC, AN, and benign prostatic hyperplasia (BPH) samples by quantitative methylation-specific PCR (qMSP) and found that MEIS2 was significantly hypermethylated (p??0.84. Moreover, in this cohort, aberrant MEIS2 hypermethylation was significantly associated with post-operative BCR (p?=?0.0068, log-rank test), which was subsequently confirmed (p?=?0.0067; log-rank test) in the independent TCGA validation cohort (497 RP patients; 450K data). CONCLUSIONS:To the best of our knowledge, this is the first study to investigate, demonstrate, and independently validate a prognostic biomarker potential for MEIS2 at the transcriptional expression level and at the DNA methylation level in PC.

SUBMITTER: Norgaard M 

PROVIDER: S-EPMC6805635 | biostudies-literature | 2019 Oct

REPOSITORIES: biostudies-literature

altmetric image

Publications

Epigenetic silencing of MEIS2 in prostate cancer recurrence.

Nørgaard Maibritt M   Haldrup Christa C   Bjerre Marianne Trier MT   Høyer Søren S   Ulhøi Benedicte B   Borre Michael M   Sørensen Karina D KD  

Clinical epigenetics 20191022 1


<h4>Background</h4>Current diagnostic and prognostic tools for prostate cancer (PC) are suboptimal, resulting in overdiagnosis and overtreatment of clinically insignificant tumors. Thus, to improve the management of PC, novel biomarkers are urgently needed.<h4>Results</h4>In this study, we integrated genome-wide methylome (Illumina 450K DNA methylation array (450K)) and RNA sequencing (RNAseq) data performed in a discovery set of 27 PC and 15 adjacent normal (AN) prostate tissue samples to ident  ...[more]

Similar Datasets

2011-06-15 | GSE18918 | GEO
2011-06-15 | E-GEOD-18918 | biostudies-arrayexpress
| S-EPMC6517268 | biostudies-literature
2014-09-29 | ST000104 | MetabolomicsWorkbench
| S-EPMC6249266 | biostudies-other
| S-EPMC3421953 | biostudies-literature
| S-EPMC3059497 | biostudies-literature
| S-EPMC4391120 | biostudies-literature